

Thursday, November 6, 2025

Unless otherwise indicated, the language of presentation is English.

9 : 00–10 : 30

Room 3 (Hall B7 (2), Tokyo International Forum)

JLCS-IASLC Joint Symposium

Perioperative Treatments

Chairs : Karen Kelly
International Association for the Study of Lung Cancer, USA
Nobuyuki Yamamoto
Wakayama Medical University

Greeting message (Video)

Caicun Zhou
Shanghai East Hospital, Tongji University School of Medicine, China

1. Global Directions in Perioperative Lung Cancer Care : MDT Integration and the IASLC's Mission

Karen Kelly
International Association for the Study of Lung Cancer, USA

2. Perioperative treatment for early-stage NSCLC : Japanese perspective

Hidehito Horinouchi
National Cancer Center Hospital

3. Perioperative Lung Cancer Treatment from a Surgical Perspective in Europe.

Paul Van Schil
Antwerp University Hospital, Belgium

4. Perioperative Lung Cancer Treatment : A Medical Oncology Perspective in the United States

Alex A. Adjei
Cleveland Clinic Cancer Institute Cleveland, USA

5. Perioperative Lung Cancer Treatment from a Surgical Perspective in Korea and Asia

Hong Kwan Kim
Samsung Medical Center/Sungkyunkwan University School of Medicine, Korea

11 : 20–12 : 10

Room 5 (Hall B5 (2), Tokyo International Forum)

Invited Lecture 2

Chair : Makoto Suzuki
Kumamoto University

The Hidden Driver of Post-Pandemic Cancer : Nervous System Dysregulation as the Critical Missing Link in Oncology

Malcolm V. Brock
The Johns Hopkins University School of Medicine, USA

12 : 30–13 : 20

Room 1 (Hall C, Tokyo International Forum)

Luncheon Seminar 1

Chair : Kazuhisa Takahashi
Juntendo University Graduate School of Medicine

Optimal First-line Treatment and Management for EGFR Mutant NSCLC

James Chih-Hsin Yang
The National Taiwan University Cancer Center, Taiwan

Johnson & Johnson Innovative Medicine Medical affairs division

12 : 30–13 : 20 Room 3 (Hall B7 (2), Tokyo International Forum)
Luncheon Seminar 3

Chair : Tetsuya Mitsudomi
Izumi City General Hospital/Faculty of Medicine, Kindai University

Perioperative Treatment in NSCLC : Insights from Recent Randomized Trials
Paul Van Schil
Antwerp University Hospital, Belgium

MSD K.K.

12 : 30–13 : 20 Room 5 (Hall B5 (2), Tokyo International Forum)
Luncheon Seminar 5

Chair : Satoshi Oizumi
Hokkaido Cancer Center

Tumor Treating Fields Therapy (TTFields Therapy) - A novel option for NSCLC treatment -
Ticiania A. Leal
Emory University School of Medicine, USA

Novocure K.K.

12 : 30–13 : 20 Room 9 (G502, Tokyo International Forum)
Luncheon Seminar 9

Chair : Hirotsugu Kenmotsu
Shizuoka Cancer Center

Strategies for first-line therapy of ALK-positive NSCLC
Jung Seop Eom
Pusan National University Hospital, Korea

Takeda Pharmaceutical Company Limited

14 : 20–15 : 50

Room 11 (G402, Tokyo International Forum)

Chairman's Program 2

Meet the Foreign Experts

- Moderator : Taichi Miyawaki
Juntendo University Graduate School of Medicine
- Experts : (Table A) David P. Carbone
The Ohio State University, USA
- (Table B) Heather Wakelee
Stanford University/Stanford Cancer Institute, USA
- (Table C) Charles Swanton
The Francis Crick Institute, UK
- (Table D) Malcolm V. Brock
The Johns Hopkins University School of Medicine, USA
- (Table E) Paul Van Schil
Antwerp University Hospital, Belgium
- Facilitator : (Table A) Tadaaki Yamada
Kyoto Prefectural University of Medicine
- (Table B) Motoko Tachihara
Kobe University Graduate School of Medicine
- (Table C) Masahiro Torasawa
Juntendo University Graduate School of Medicine
- (Table D) Isamu Okamoto
Graduate School of Medical Sciences, Kyushu University
- (Table E) Yujin Kudo
Tokyo Medical University

15 : 40–17 : 20

Room 3 (Hall B7 (2), Tokyo International Forum)

Joint Session : Early Career Support Committee/International Committee

- Chairs : Kazuyoshi Imaizumi
Fujita Health University
- Makoto Nishio
Cancer Institute Hospital of Japanese Foundation for Cancer Research

1. Activities of the Early Career Committee

Hiroaki Akamatsu
Wakayama Medical University

2. Early Career Supporting Committee and International Committee Joint Session

Hidehito Horinouchi
National Cancer Center Hospital

3. IASLC Initiatives for Developing Young Talent

Karen Kelly
International Association for the Study of Lung Cancer, USA

4. Real-World Treatment Strategy and Postoperative Prognosis for Clinical Stage II/III NSCLC : A Multicenter Study

Taichi Matsubara
Kyushu University Hospital / Graduate School of Medical Sciences, Kyushu University

5. Constitutive activation of EGFR induced by downregulation of PTPRR confers resistance to KRAS inhibitors

Hiroaki Kanemura
Kindai University Faculty of Medicine

6. The biomarker research of Marble study - Atezolizumab+CBDCA+PTX in patients with thymic carcinoma

Yukina Shirai

Juntendo University Graduate School of Medicine

16 : 20-17 : 10

Room 1 (Hall C, Tokyo International Forum)

Invited Lecture 1

Chair : Takashi Kohno

National Cancer Center Research Institute

Lung Cancer Promotion and Prevention : Myeloid mayhem

Charles Swanton

The Francis Crick Institute, UK

17 : 30-18 : 20

Room 4 (Hall B5 (1), Tokyo International Forum)

Evening Seminar 2

**Perioperative treatment of Non-Small Cell Lung Cancer - determine indication for Neoadjuvant therapy/
Adjuvant therapy -**

Chair : Terufumi Kato

Tokyo Metropolitan Komagome Hospital

1. Review of treatment using ICI in the perioperative period

Heather Wakelee

Stanford University/Stanford Cancer Institute, USA

2. From Operability to Resectability : A Surgeon's Perspective on Locally Advanced NSCLC

Japanese

Hiroyuki Ito

Kanagawa Cancer Center

CHUGAI PHARMACEUTICAL CO., LTD.